<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/22/weekly-research-analysts-ratings-updates-for-aptinyx-aptx.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-22T18:42:42+00:00"/>
    <meta property="og:title" content="Weekly Research Analysts’ Ratings Updates for Aptinyx (APTX)"/>
    <meta property="og:description" content="Several analysts have recently updated their ratings and price targets for Aptinyx (NASDAQ: APTX): 11/15/2019 – Aptinyx was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small […]"/>
  </head>
  <body>
    <article>
      <h1>Weekly Research Analysts’ Ratings Updates for Aptinyx (APTX)</h1>
      <address><time datetime="2019-11-22T18:42:42+00:00">22 Nov 2019, 18:42</time> by <a rel="author" href="https://www.thecerbatgem.com/author/scott" target="_blank">Scott Moore</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/aptinyx-inc-logo.png"/>
      </figure>
      <p>Several analysts have recently updated their ratings and price targets for <b>Aptinyx</b> (NASDAQ: APTX):</p>
      <ul>
        <li>11/15/2019 – Aptinyx was upgraded by analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> from a “sell” rating to a “hold” rating. According to Zacks, “Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company’s product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. “</li>
        <li>11/14/2019 – Aptinyx had its “buy” rating reaffirmed by analysts at Cowen Inc.</li>
        <li>11/13/2019 – Aptinyx had its price target lowered by analysts at BMO Capital Markets from $15.00 to $13.00. They now have an “outperform” rating on the stock.</li>
        <li>11/8/2019 – Aptinyx was downgraded by analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> from a “hold” rating to a “sell” rating. According to Zacks, “Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company’s product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. “</li>
        <li>10/15/2019 – Aptinyx was downgraded by analysts at <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> from a “buy” rating to a “hold” rating. According to Zacks, “Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company’s product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States. “</li>
      </ul>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NASDAQ/APTX/price-target/">APTX</a> traded down $0.10 during trading hours on Friday, reaching $3.10. The stock had a trading volume of 146,446 shares, compared to its average volume of 268,631. Aptinyx Inc has a 52 week low of $2.61 and a 52 week high of $26.74. The firm has a 50-day moving average of $3.21 and a 200 day moving average of $3.43. The company has a market cap of $107.40 million, a P/E ratio of -1.17 and a beta of 0.01.</p>
      <p>Aptinyx (NASDAQ:APTX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.44) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.44). Aptinyx had a negative net margin of 1,523.09% and a negative return on equity of 44.24%. The business had revenue of $0.94 million during the quarter, compared to analysts’ expectations of $0.91 million. Equities analysts forecast that Aptinyx Inc will post -1.92 earnings per share for the current year.</p>
      <p>Several institutional investors and hedge funds have recently added to or reduced their stakes in APTX. SG Americas Securities LLC bought a new stake in shares of Aptinyx in the 2nd quarter valued at $49,000. Gabelli Funds LLC increased its holdings in Aptinyx by 45.9% during the 2nd quarter. Gabelli Funds LLC now owns 15,901 shares of the company’s stock worth $53,000 after purchasing an additional 5,000 shares in the last quarter. Acadian Asset Management LLC bought a new position in Aptinyx during the 2nd quarter worth about $195,000. Jacobs Levy Equity Management Inc. bought a new position in Aptinyx during the 2nd quarter worth about $54,000. Finally, Weiss Asset Management LP bought a new position in Aptinyx during the 2nd quarter worth about $65,000. Institutional investors and hedge funds own 52.14% of the company’s stock.</p>
      <p>Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.</p>
      <p>Read More: <a href="https://www.marketbeat.com/financial-terms/what-is-cash-asset-ratio/">What is the formula for the cash asset ratio?</a></p>
    </article>
  </body>
</html>